Insmed Incorporated (NASDAQ:INSM) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP reduced its holdings in Insmed Incorporated (NASDAQ:INSM) by 16.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 326,500 shares of the biopharmaceutical company’s stock after selling 66,200 shares during the period. Two Sigma Advisers LP owned about 0.18% of Insmed worth $22,542,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Tema Etfs LLC acquired a new position in Insmed during the fourth quarter worth $734,000. Stempoint Capital LP acquired a new position in shares of Insmed during the 4th quarter worth about $7,360,000. Snowden Capital Advisors LLC lifted its stake in Insmed by 2.5% in the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 158 shares in the last quarter. Polar Capital Holdings Plc boosted its holdings in Insmed by 7.4% in the 4th quarter. Polar Capital Holdings Plc now owns 730,000 shares of the biopharmaceutical company’s stock worth $50,399,000 after buying an additional 50,000 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in Insmed by 43.0% in the 4th quarter. ProShare Advisors LLC now owns 56,991 shares of the biopharmaceutical company’s stock worth $3,935,000 after buying an additional 17,141 shares during the last quarter.

Insmed Stock Performance

Insmed stock opened at $68.51 on Wednesday. The firm has a 50 day simple moving average of $71.32 and a 200-day simple moving average of $73.13. The stock has a market cap of $12.48 billion, a price-to-earnings ratio of -12.26 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. During the same period last year, the business earned ($1.06) EPS. Insmed’s revenue was up 22.9% compared to the same quarter last year. On average, analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on INSM. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. UBS Group reduced their price objective on Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Truist Financial lifted their target price on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Stifel Nicolaus dropped their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Finally, Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and an average target price of $94.63.

Insiders Place Their Bets

In related news, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,742,347.58. The trade was a 5.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Martina M.D. Flammer sold 9,925 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $65.47, for a total value of $649,789.75. Following the transaction, the insider now directly owns 86,596 shares in the company, valued at approximately $5,669,440.12. The trade was a 10.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 125,211 shares of company stock valued at $8,837,158 over the last 90 days. 3.00% of the stock is owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.